Alerts will be sent to your verified email
Verify Email
BACPHAR
|
Bacil Pharma
|
Accretion Pharma.
|
Makers Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
0.32 % | 35.81 % | 3.8 % |
|
5yr average Equity Multiplier
|
1.36 | 3.8 | 2.36 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.96 | 0.7 |
|
5yr Avg Net Profit Margin
|
0.0 | 11.51 % | -0.21 % |
|
Price to Book
|
3.23 | 0.0 | 1.31 |
|
P/E
|
114.86 | 13.25 | 76.79 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 102.38 Days | 75.08 Days |
|
Inventory Days
|
0.0 | 253.65 Days | 107.1 Days |
|
Days Receivable
|
0.0 | 55.55 Days | 71.83 Days |
|
Days Payable
|
0.0 | 160.55 Days | 106.28 Days |
|
5yr Average Interest Coverage Ratio
|
-943.72 | 6.89 | 4.73 |
|
5yr Avg ROCE
|
-75.56 % | 43.29 % | 6.35 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 19.95 % | 7.59 % |
|
5 yr average Debt to Equity
|
0.05 | 1.69 | 0.21 |
|
5yr CAGR Net Profit
|
n/a | 143.08 % | n/a |
|
5yr Average Return on Assets
|
-70.2 % | 11.24 % | 0.25 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.08 % | 73.52 % | 61.27 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-42.59 % | 0.01 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bacil Pharma
|
Accretion Pharma.
|
Makers Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|